Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
DualityBio Inc.
Lumicell, Inc.
BicycleTx Limited
Bolt Biotherapeutics, Inc.
Marengo Therapeutics, Inc.
Revolution Medicines, Inc.
University of Maryland, Baltimore
Mirror Biologics, Inc.
Radboud University Medical Center